University of Kentucky, Neurology and Movement Disorder
Welcome,         Profile    Billing    Logout  
 5 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Slevin, John T
C-SAPP, NCT04373317: Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

Recruiting
4
358
US
Pimavanserin, Quetiapine
VA Office of Research and Development
Parkinson's Disease Psychosis
10/25
08/26
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Active, not recruiting
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
10/24
02/25
NCT03481283: A Causative Role for Amylin in Diabetic Peripheral Neuropathy

Recruiting
N/A
40
US
Zabeen Mahuwala, MD
Type2 Diabetes, Peripheral Neuropathy
01/29
01/29
AIDP, NCT05913687: Automated Imaging Differentiation of Parkinsonism

Active, not recruiting
N/A
315
Canada, US
AIDP
University of Florida, Augusta University, Albany Medical College, Beth Israel Deaconess Medical Center, Duke University, Johns Hopkins University, Massachusetts General Hospital, Northwestern University, Ottawa Hospital Research Institute, Penn State University, University of Alabama at Birmingham, University of California, San Diego, University of California, San Francisco, University of Chicago, University of Michigan, University of Minnesota, University of South Florida, Centre for Addiction and Mental Health, Wake Forest University, Washington University School of Medicine, University of Kentucky, National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
03/26
03/26
Wagner, Renee
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting
N/A
25000
Canada, US, RoW
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group
Parkinson's Disease
12/24
06/25
AIDP, NCT05913687: Automated Imaging Differentiation of Parkinsonism

Active, not recruiting
N/A
315
Canada, US
AIDP
University of Florida, Augusta University, Albany Medical College, Beth Israel Deaconess Medical Center, Duke University, Johns Hopkins University, Massachusetts General Hospital, Northwestern University, Ottawa Hospital Research Institute, Penn State University, University of Alabama at Birmingham, University of California, San Diego, University of California, San Francisco, University of Chicago, University of Michigan, University of Minnesota, University of South Florida, Centre for Addiction and Mental Health, Wake Forest University, Washington University School of Medicine, University of Kentucky, National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
03/26
03/26

Download Options